Category: Technology Licenses
Created On: 2022-04-28
Record Count: 13
- HIV / AIDs
- Drug Discovery
- Viral Infection
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 299287
The patents include Improved vaccines and methods for using the same; Novel vaccines against multiple subtypes of influenza virus; Influenza Nucleic acid molecules and vaccines made therefrom; and, Nucleic acid molecule encoding concensus influenza a hemagglutinin H!
SynConâ„¢ technology enables the design of â€œuniversalâ€ DNA-based vaccines capable of providing cross-protection against new, unmatched strains of pathogens such as influenza.
IPSCIO Record ID: 27993
The parties desire for Licensee to develop, manufacture, market, distribute and sell a product for treating or preventing influenza virus and/or infection, such as a vaccine comprising antigenic determinants of an influenza virus, like FluogenÂ®, which includes a proprietary adjuvant developed by Licensor.
IPSCIO Record ID: 371191
Epitopes or protein of antigens which can be utilized to develop singular or multi-targeted vaccines. Epitopes can simply be fused to the end of the S domain via flexible linker through recombinant DNA technology. Identified epitopes of limited variability in H1 influenza that have circulated throughout history (since 1918) and make ideal vaccine targets and have completed similar analysis of H3 and Flu B strains for similar epitopes which will be used to produce our lead vaccine candidate BWV-101 as a universal vaccine for influenza infection. Due to the cross-reactive nature of the H1 epitopes in pre-pandemic H1 influenza A, companies are pursuing the development of a stand-alone H1 vaccine (BWV-102). These epitopes are able to be formulated into a vaccine candidate using the VLP platform technologies and may be evaluated using other vaccine technologies through partnerships in order to accelerate development of potential vaccines or to explore adjunct therapies.
Field of use is for the treatment of influenza.
IPSCIO Record ID: 4244
VLPs are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins. The Companyâ€™s VLPs resemble the virus they were engineered to mimic, but lack the genetic material to replicate the virus and its single-use bioprocessing production technology uses insect cells rather than chicken eggs or mammalian cells.
The Licensorâ€™s current product targets include VLP vaccines against seasonal and pandemic (including H5N1) influenza and a recombinant nanoparticle vaccine against Respiratory Syncytial Virus (RSV).
The upfront payment has been deferred and will be recognized as revenue when certain obligations in the agreement are satisfied.
IPSCIO Record ID: 27555
A Sublicence under the Licence may be granted by the Licensee only with the prior written consent of the Licensor.
IPSCIO Record ID: 328343
AIDS Vaccine means a vaccine which would prevent an infection by Human Immunodeficiency Virus (HIV-1) and/or clinical diseases caused by infection with HIV-1 in humans.
Influenza Vaccine means a vaccine which would prevent an infection and/or significant clinical diseases caused by any influenza virus in humans.
Licensed Product means a bulk or finished AIDS Vaccine or Influenza Vaccine, or other vaccine for the prevention of human infectious disease if licensed hereunder, which utilizes the Technology or technology which is developed by Licensor during and as a result of the Research Collaboration Program; provided, however, that if any such vaccine is also capable of being used for treatment of the same human infectious disease, then such therapeutic use of such vaccine shall also be considered a Licensed Product for purposes of the license being granted by Licensor to Licensee under this Agreement.
IPSCIO Record ID: 340468
Licensor will grant to Licensee an exclusive, worldwide license under Licensors rights in certain patents and related intellectual property, or the License, in which Licensee will receive certain rights relating to Licensorâ€™s proprietary oral delivery technology to further develop, manufacture and commercialize oral vaccines for COVID-19 and other novel coronaviruses based on proprietary vaccine technology involving a triple antigen virus like particle, or the Product.
Licensed IP means Patent Rights, Know-How and Information related to Licensorâ€™s proprietary PODTM oral delivery technology involving a triple antigen virus like particle, or the Product.
The oral COVID-19 vaccine being developed promoted both systemic immunity through Immunoglobulin G (IgG), the most common antibody in blood and bodily fluids that protects against viral infections, and Immunoglobulin A (IgA).
Licensee is focused on the development of novel oral COVID-19 vaccines based on Licensorâ€™s proprietary PODTM oral delivery technology as well as novel vaccine technology that was previously assigned to Licensee.
IPSCIO Record ID: 368651
This agreement includes a non-exclusive grant back from Licensee to Licensor.
The Compound is designated by Licensor as Resiquimod (R-848), S36212, 1-(4-aminobutoxy) -2-butyl-lH-imidazo (4,5-cl quinolin-4-amine and conjugates thereof.
Product shall mean any combination of a Licensee Antigen Presenting Cell or APC Targeting Technology vaccine with a Licensed Compound to be utilized as a Vaccine Adjuvant.
Vaccine Adjuvant shall mean a Licensed Compound which is used to induce, augment, fine-tune, enhance, or desensitize an antigen-specific immune response to an antigen contained in a vaccine or generated by a DNA vaccine for the therapeutic treatment of an existing disease or prophylactic use as protection against future disease, including desensitization to allergens. The antigen and the vaccine adjuvant may be admixed, delivered simultaneously, conjugated, or delivered separately, provided however, that the separate administration of the antigen and vaccine adjuvant is limited to the topical, dermal or mucosal or intradermal routes of administration and must be administered within 48 hours at substantially the same site and labeled as such by the applicable regulatory authority.
TLR compounds, also called TLR7 and TLR8 agonists, are small organically synthesized molecules that offer flexibility in formulating and route of delivery, and ease in manufacturing, unlike most other TLR agonists, which are much larger and not as easy to manufacture.
The Field shall mean human prophylactic or therapeutic vaccination against any and all cancer disease states and selected infectious diseases.
This agreement focus is Cancer and the Infectious Diseases
– human immunodeficiency virus (HIV);
– human papillomavirus (HPV); and,
– hepatitis B virus (HBV).
IPSCIO Record ID: 257492
With this amendment the parties wish to amend the Agreement to provide for the reversion of rights to Licensor under the Licensor patent rights and know-how for Influenza vaccine, HPV vaccine and HSV vaccine.
As of the Amendment Effective Date, the license granted to Licensee, and the rights and obligations of Licensee and Licensor arising therefrom, shall no longer apply to Influenza vaccine, HPV Vaccine and HSV Vaccine, and these vaccines shall no longer be deemed to be Licensed Products under the Agreement.
Hereby amended Licensor grants to Licensee an exclusive license, even as to Licensor, under Licensor know-how and patent rights to develop, make, have made, use and sell Licensed products in the Territory with the right to grant sub licenses to Affiliates of Licensee and those persons or entities through whom Licensee, in the normal course of its business collaborates in the manufacture and sale of its products; provided however, that nothing in this Agreement shall prohibit Licensor from utilizing the Licensor know-how and/or patent rights, exclusive of Licensee know-how, to develop, make, have made, use and sell, either by itself or with one or more third parties, products for the treatment of infectious diseases provided, further, notwithstanding the preceding proviso, that Licensor shall not have any right to develop, make, have made, use, or sell, either by itself or with one or more third parties, Treatment Vaccines.
Licensor grants an option to obtain a license under theLicensor patent rights and know-how to make, have made, use, sell, offer to sell and import Cancer Vaccines in the Territory for up to three (3) Cancer targets. Such Cancer target license shall be exclusive, even as to Licensor, for each Cancer Target so licensed, and shall be sublicenseable by Licensee pursuant to the terms applicable to Licensed Products.
Treatment vaccines means a bulk or finished vaccine.
IPSCIO Record ID: 275801
Licensed Product shall mean any HIV vaccine product other than the HIV Vaccine that cannot be developed, manufactured, used, or sold without infringing one or more Valid Claim under the Patent Rights.
The patents are titled Polyvalent, Primary HIV -1 Envelope Glycoprotein DNA Vaccine, and, Polyvalent DNA and Protein Vaccines.
This technology is a DNA-based HIV vaccine that incorporates the 03-24 Technology and the 03-111 Technology. Invention disclosure number 03-24 is entitled Primary and Polyvalent IIlV-1 Envelope Glycoprotein DNA Vaccines. And HIV protein boost technology invention is referred to as 03-111.
New Vaccine shall mean any HIV vaccine other than the HIV Vaccine.
IPSCIO Record ID: 273729
The '03-111 Technology – U. S. Patent Application Serial Number 60/503,907 (the '03-111 Patent Filing') covering an HIV protein boost technology invention referred to by University and Licensee as UMMC 03-111.
IPSCIO Record ID: 28542
Application serial #08/130,986 Protein or Peptide-Cochleate vaccines and methods of immunizing using the same.
IPSCIO Record ID: 237265
Licensor grants a non-exclusive, sublicensable license to Licensors Intellectual Property in the Territory solely to use and import nucleic acid sequences encoding for such Additional Antigen in the Field, and to make, have made, use, sell, offer to sell and import Licensee Product(s) containing a nucleic acid sequence encoding for such Additional Antigen in the Field.
For the Licensors Applicator and/or Licensors Custom Components, Licensor grants an exclusive, sublicenseable license under the Licensors Patent Rights and Device Custom Know-How to use, sell, offer to sell and import Licensors Applicators and Licensors Custom Components solely for use with a Licensee Product in the Field.
For the Trademark License, Licensor grants a non-exclusive, sublicensable license in the Field in the Territory to use such trademarks and/or trade names Controlled by Licensor, to the extent that such trademarks and/or trade names relate to Licensors Technology, solely in connection with the use, sale, offer to sell and/or import of Licensee Product.
A single Indication shall include the primary disease and variants or sub-divisions or sub-classifications within such primary disease. For example, for purposes of the Agreement, breast cancer is a single Indication; treatment of and first line treatment of refractory metastatic breast cancer shall be treated as sub-classifications within the single Indication of breast cancer. Treatment and prophylaxis of the same disease (e.g. breast cancer) shall be treated as the same Indication.